Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists

被引:61
作者
Keenan, RM
Callahan, JF
Samanen, JM
Bondinell, WE
Calvo, RR
Chen, LC
DeBrosse, C
Eggleston, DS
Haltiwanger, RC
Hwang, SM
Jakas, DR
Ku, TW
Miller, WH
Newlander, KA
Nichols, A
Parker, MF
Southhall, LS
Uzinskas, I
Vasko-Moser, JA
Venslavsky, JW
Wong, AS
Huffman, WF
机构
[1] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Med Chem, Collegeville, PA 19426 USA
[2] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Cellular Biochem, Collegeville, PA 19426 USA
[3] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Cardiovasc Pharmacol, Collegeville, PA 19426 USA
[4] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Analyt Chem, Collegeville, PA 19426 USA
[5] SmithKline Beecham Pharmaceut, Div Res & Dev, Dept Phys & Struct Chem, Collegeville, PA 19426 USA
关键词
D O I
10.1021/jm980166z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Previously, we reported the direct design of highly potent nonpeptide 3-oxo-1,4-benzodiazepine fibrinogen receptor antagonists from a constrained, RGD-containing cyclic semipeptide. The critical features incorporated into the design of these nonpeptides were the exocyclic amide at the 8-position which overlaid the Arg carbonyl, the phenyl ring which maintained an extended Gly conformation, and the diazepine ring which mimicked the gamma-turn at Asp. In this paper, we investigate conformational preferences of the 8-substituted benzodiazepine analogues by examining structural modifications to both the exocyclic amide and the seven-membered diazepine ring and by studying the conformation of the benzodiazepine ring using molecular modeling, X-ray crystallography, and NMR. We found that the directionality of the amide at the 8-position had little effect on activity and the (E)-olefin analogue retained significant potency, indicating that the trans orientation of the amide, and not the carbonyl or NH groups, made the largest contribution to the observed activity. For the diazepine ring, with the exception of the closely analogous 3-oxo-2-benzazepine ring system described previously, all of the modifications led to a significant reduction in activity compared to the potent 3-oxo-1,4-benzodiazepine parent ring system, implicating this particular type of ring system as a desirable structural feature for high potency. Energy minimizations of a number of the modified analogues revealed that none could adopt the same low-energy conformation as the one shared by the active (S)-isomer of the 3-oxo-1,4-benzodiazepines and 3-oxo-2-benzazepines. The overall data suggest that the features contributing to the observed high potency in this series are the orientation of the 3-4 amide and the conformational constraint imposed by the seven-membered ring, both of which position the key acidic acid basic groups in the proper spatial relationship.
引用
收藏
页码:545 / 559
页数:15
相关论文
共 36 条
[21]   FROM PEPTIDE TO NONPEPTIDE .2. THE DE-NOVO DESIGN OF POTENT, NON-PEPTIDAL INHIBITORS OF PLATELET-AGGREGATION BASED ON A BENZODIAZEPINEDIONE SCAFFOLD [J].
MCDOWELL, RS ;
BLACKBURN, BK ;
GADEK, TR ;
MCGEE, LR ;
RAWSON, T ;
REYNOLDS, ME ;
ROBARGE, KD ;
SOMERS, TC ;
THORSETT, ED ;
TISCHLER, M ;
WEBB, RR ;
VENUTI, MC .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (12) :5077-5083
[22]   FROM PEPTIDE TO NONPEPTIDE .1. THE ELUCIDATION OF A BIOACTIVE CONFORMATION OF THE ARGININE-GLYCINE-ASPARTIC ACID RECOGNITION SEQUENCE [J].
MCDOWELL, RS ;
GADEK, TR ;
BARKER, PL ;
BURDICK, DJ ;
CHAN, KS ;
QUAN, CL ;
SKELTON, N ;
STRUBLE, M ;
THORSETT, ED ;
TISCHLER, M ;
TOM, JYK ;
WEBB, TR ;
BURNIER, JP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (12) :5069-5076
[23]   SYNTHESIS OF A 2-BENZAZEPINE ANALOG OF A POTENT, NONPEPTIDE GPIIB/IIIA ANTAGONIST [J].
MILLER, WH ;
NEWLANDER, KA ;
EGGLESTON, DS ;
HALTIWANGER, RC .
TETRAHEDRON LETTERS, 1995, 36 (03) :373-376
[24]   Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine series [J].
Miller, WH ;
Ali, FE ;
Bondinell, WE ;
Callahan, JF ;
Calvo, RR ;
Eggleston, DS ;
Haltiwanger, RC ;
Huffman, WF ;
Hwang, SM ;
Jakas, DR ;
Keenan, RM ;
Koster, PF ;
Ku, TW ;
Kwon, C ;
Newlander, KA ;
Nichols, AJ ;
Parker, MF ;
Samanen, JM ;
Southall, LS ;
Takata, DT ;
Uzinskas, IN ;
Valocik, RE ;
VaskoMoser, JA ;
Wong, AS ;
Yellin, TO ;
Yuan, CCK .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (21) :2481-2486
[25]   PHARMACOPHORE REFINEMENT OF GPIIB/IIIA ANTAGONISTS BASED ON COMPARATIVE-STUDIES OF ANTIADHESIVE CYCLIC AND ACYCLIC RGD PEPTIDES [J].
MULLER, G ;
GURRATH, M ;
KESSLER, H .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1994, 8 (06) :709-730
[26]   DEVELOPMENT OF GPIIB IIIA ANTAGONISTS AS ANTITHROMBOTIC DRUGS [J].
NICHOLS, AJ ;
RUFFOLO, RR ;
HUFFMAN, WF ;
POSTE, G ;
SAMANEN, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (11) :413-417
[27]  
NUTT RF, 1992, PEPTIDES CHEM BIOL, P914
[28]  
OJIMA L, 1995, BIOORGAN MED CHEM, V3, P337
[29]   INVESTIGATION OF CONFORMATIONAL SPECIFICITY AT GPIIB/IIIA - EVALUATION OF CONFORMATIONALLY CONSTRAINED RGD PEPTIDES [J].
PEISHOFF, CE ;
ALI, FE ;
BEAN, JW ;
CALVO, R ;
DAMBROSIO, CA ;
EGGLESTON, DS ;
HWANG, SM ;
KLINE, TP ;
KOSTER, PF ;
NICHOLS, A ;
POWERS, D ;
ROMOFF, T ;
SAMANEN, JM ;
STADEL, J ;
VASKO, JA ;
KOPPLE, KD .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (21) :3962-3969
[30]   GPIIb/IIIa antagonists [J].
Samanen, J .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31, 1996, 31 :91-100